Home›Testosterone

Testosterone

AndrogenAndrogen Receptor Agonists

Route: Topical

16 interactions on record⛔ Black Box Warning

Testosterone has 16 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Corticosteroids, Insulin Human, Oral Anticoagulants. Patients taking Testosterone should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 16
Moderate: 5
Minor: 1

Moderate (5)

Testosterone + Corticosteroids— Concurrent use with testosterone may result in increased fluid retention. Use with caution, particularly in patients wit…
Testosterone + Insulin Human— Androgens may decrease blood glucose and insulin requirement in diabetic patients. Changes in insulin sensitivity or gly…
Testosterone + Oral Anticoagulants— Changes in anticoagulant activity may occur with androgens. More frequent monitoring of INR and prothrombin time is reco…
Testosterone + Repository Corticotropin— Concurrent use with testosterone may result in increased fluid retention. Use with caution, particularly in patients wit…
Testosterone + Warfarin— Androgens may alter anticoagulant activity; more frequent monitoring of INR and prothrombin time is recommended, especia…

Minor (1)

Testosterone + Oxymetazoline— Oxymetazoline decreased mean AUC and Cmax of total testosterone by 2.6% and 3.6% respectively when given 30 minutes prio…

Testosterone + Corticosteroids🟡Moderate

Concurrent use with testosterone may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Testosterone + Insulin Human🟡Moderate

Androgens may decrease blood glucose and insulin requirement in diabetic patients. Changes in insulin sensitivity or glycemic control may occur.

Testosterone + Oral Anticoagulants🟡Moderate

Changes in anticoagulant activity may occur with androgens. More frequent monitoring of INR and prothrombin time is recommended, especially at initiation and termination of therapy.

Testosterone + Repository Corticotropin🟡Moderate

Concurrent use with testosterone may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Testosterone + Warfarin🟡Moderate

Androgens may alter anticoagulant activity; more frequent monitoring of INR and prothrombin time is recommended, especially at initiation and termination of therapy.

Testosterone + Oxymetazoline🟢Minor

Oxymetazoline decreased mean AUC and Cmax of total testosterone by 2.6% and 3.6% respectively when given 30 minutes prior to testosterone; no clinically significant impact on absorption.

Testosterone + Esterified Estrogens, Methyltestosteroneℹ️Unknown

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants.

Testosterone + Estradiolℹ️Unknown

Free hormone concentrations, such as testosterone and estradiol, may be decreased.

Testosterone + Lovastatinℹ️Unknown

However, clinical studies have shown that lovastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve, and does not reduce basal plasma testosterone concentration. Another HMG-CoA reductase inhibitor has been shown to reduce the plasma testosterone response to HCG. In the same study, the mean testosterone response to HCG was slightly but not significantly reduced after treatment with lovastatin 40 mg daily for 16 weeks in 21 men.

Testosterone + Medroxyprogesterone Acetateℹ️Unknown

The following laboratory tests may be affected by progestins including medroxyprogesterone acetate injectable suspension: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol).

Testosterone + Methyltestosteroneℹ️Unknown

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants.

Testosterone + Pregabalinℹ️Unknown

Therefore, an increase in the metabolism of coadministered CYP1A2 substrates (e.g., theophylline, caffeine) or CYP3A4 substrates (e.g., midazolam, testosterone) is not anticipated.

Testosterone + Testosterone Cypionateℹ️Unknown

7.3 Corticosteroids The concurrent use of testosterone with corticosteroids may result in increased fluid retention and should be monitored cautiously, particularly in patients with cardiac, renal or hepatic disease.

Testosterone + Testosterone Enanthateℹ️Unknown

Use of testosterone with corticosteroids may result in increased fluid retention. 7.3 Corticosteroids The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring, particularly in patients with cardiac, renal or hepatic disease.

Testosterone + Testosterone Gel, 1%ℹ️Unknown

( 7.2 ) Use of testosterone with adrenocorticotrophic hormone (ACTH) or corticosteroids may result in increased fluid retention. 7.3 Corticosteroids The concurrent use of testosterone with adrenocorticotropic hormone (ACTH) or corticosteroids may result in increased fluid retention and requires careful monitoring particularly in patients with cardiac, renal or hepatic disease.

Testosterone + Testosterone Undecanoateℹ️Unknown

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.